Cost-effectiveness of the treatment and prevention of osteoporosis -: a review of the literature and a reference model

被引:136
作者
Zethraeus, N.
Borgstrom, F.
Strom, O.
Kanis, J. A. [1 ]
Jonsson, B.
机构
[1] Univ Sheffield, Sch Med, Ctr Metab Bone Dis, WHO Collaborating Ctr, Sheffield S10 2RX, S Yorkshire, England
[2] Stockholm Sch Econ, Ctr Hlth Econ, S-11383 Stockholm, Sweden
[3] Stockholm Hlth Econ, SE-11120 Stockholm, Sweden
[4] Karolinska Inst, Med Management Ctr, Stockholm, Sweden
关键词
cost-effectiveness; osteoporosis; prevention;
D O I
10.1007/s00198-006-0257-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The purpose of the paper is to update and review the latest developments related to modelling and economic evaluation of osteoporosis in the period 2002-2005 and further to present a reference model for the assessment of the cost-effectiveness of the prevention and treatment of osteoporosis. Discussion The reference model is intended to be used for fracture specific interventions affecting the risk of fracture. An interface version and an extensive description of the model is available on the internet (http://www.healtheconomics.se) and also accessible via the International Osteoporosis Foundation (http://www.osteofound.org). The purpose of the reference model is to improve the quality and comparability of cost-effectiveness analysis in the osteoporosis field and to serve as a tool for validation of present and future cost-effectiveness models. The reference model allows the cost-effectiveness analysis to be carried out from a societal perspective including intervention, morbidity and mortality costs. The model has been extensively tested and calibrated, and meets the properties of good decision analytic modelling. The model is a state transition Markov cohort model, which is characterised by a 50-year time horizon divided into one year cycle lengths. The following health states are included: "healthy", "hip fracture", "spine fracture", "wrist fracture", "other fracture", and "dead". Conclusion The model is flexible and allows for the estimation of the cost-effectiveness over different ranges for a selected number of variables (e.g., age, fracture risk, cost of intervention).
引用
收藏
页码:9 / 23
页数:15
相关论文
共 84 条
[1]  
Akehurst R, 2000, PHARMACOECONOMICS, V17, P443
[2]   Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus -: Results from the DIGAMI study [J].
Almbrand, B ;
Johannesson, M ;
Sjöstrand, B ;
Malmberg, K ;
Rydén, L .
EUROPEAN HEART JOURNAL, 2000, 21 (09) :733-739
[3]   Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[4]  
BAGGER YZ, 2005, OSTEOPOROSIS INT, P1
[5]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[6]   Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden -: An economic evaluation based on the MORE study [J].
Borgström, F ;
Johnell, O ;
Kanis, JA ;
Oden, A ;
Sykes, D ;
Jönsson, B .
PHARMACOECONOMICS, 2004, 22 (17) :1153-1165
[7]   Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden [J].
Borgström, F ;
Johnell, O ;
Jöhnsson, B ;
Zethraeus, N ;
Sen, SS .
BONE, 2004, 34 (06) :1064-1071
[8]  
BORGSTROM F, 2005, IN PRESS OSTEOPOPROS
[9]  
Borgstrom Fredrik, 2003, Lakartidningen, V100, P36
[10]  
Brecht JG, 2004, INT J CLIN PHARM RES, V24, P1